Elion in virology: breakthroughs deserve clear communication
Elion Medical Communications supports clients across all aspects of the vaccine development lifecycle. From emerging pathogens to next-generation platforms, we help transform complex data into compelling content that informs, educates and engages. Whether you're sharing study results, educating healthcare professionals (HCPs) or shaping public awareness, we work with you to communicate the science of vaccines clearly and effectively.
Leading with experience
At Elion, we offer expert medical writing and project management support to help pharmaceutical, biotech and public health teams communicate vaccine-related developments with clarity and impact. Our writers have experience that spans infectious disease, immunology, vaccines and virology, enabling us to translate complex science into meaningful content for diverse audiences.
Our experience includes supporting manuscripts on vaccine safety and immunogenicity in adult populations, mRNA and protein-based COVID-19 vaccines and regional perspectives on paediatric immunisation strategies. This includes work on early-phase clinical trial reporting and population-specific vaccination challenges.
We follow the latest scientific literature and publication standards to ensure your materials are accurate, relevant and aligned with current scientific developments.
Vaccine communications in step with emerging challenges
As vaccine technologies evolve, so too do the expectations around how they are communicated.
From mRNA to uptake metrics, audiences want information that is clear, grounded in science and easy to act on. We work with clients to meet that need with content that supports informed decision-making, increases understanding and drives engagement.
This need is amplified as scientific progress in virology and immunisation continues to accelerate, with innovations in delivery platforms, global surveillance and disease prevention strategies. Each breakthrough brings new opportunities to protect global health and requires clear communication that can inform clinicians, engage communities and support public health decision-making. At Elion, we support teams working at the dynamic intersection of emerging science, evolving policy and real-world impact.
Vaccine communications in step with emerging challenges
As vaccine technologies evolve, so too do the expectations around how they are communicated.
From mRNA to uptake metrics, audiences want information that is clear, grounded in science and easy to act on. We work with clients to meet that need with content that supports informed decision-making, increases understanding and drives engagement.
This need is amplified as scientific progress in virology and immunisation continues to accelerate, with innovations in delivery platforms, global surveillance and disease prevention strategies. Each breakthrough brings new opportunities to protect global health and requires clear communication that can inform clinicians, engage communities and support public health decision-making. At Elion, we support teams working at the dynamic intersection of emerging science, evolving policy and real-world impact.
Virology areas where we have made an impact
mRNA vaccine platforms
mRNA-based vaccines represent a major leap in immunisation technology. By delivering genetic instructions to host cells, they trigger targeted immune responses without introducing live pathogens. These platforms are highly adaptable, offering rapid development for emerging threats and customisation for specific populations.
Conjugate and protein subunit vaccines
These vaccines use purified components of a pathogen, such as polysaccharides or proteins, to safely induce immunity. Conjugation to a carrier protein enhances immunogenicity, especially in paediatric populations. Conjugate technologies remain essential in protecting against diseases such as pneumococcus and meningococcus.
Viral vector vaccines
Vector-based vaccines use harmless viruses as delivery vehicles for genetic material. These platforms have played a key role in recent outbreak responses and continue to be explored for both infectious diseases and cancer immunotherapy.
Adjuvants and formulation innovations
Advances in adjuvant science, from saponins and alum to emulsion-based systems, are expanding the efficacy and durability of vaccines, especially for older adults and immunocompromised populations. Thermostable formulations and needle-free delivery are improving access and equity.
Real-world data and global immunisation strategies
Evaluating vaccine effectiveness, uptake and safety in real-world settings is essential for guiding policy. Our work has supported content related to post-marketing surveillance and public health strategy communications.
Our work in virology
The types of deliverables we’ve contributed to include:
- peer-reviewed publications and narrative summaries
- educational materials for HCPs
- scientific congress content (posters, abstracts and presentations)
- patient information and awareness resources
- internal training decks and speaker support slides
- content for multichannel campaigns and engagement strategies
- post-meeting materials for advisory boards and expert groups.
Vaccine areas we’re familiar with
- mRNA and lipid nanoparticle technologies
- Conjugate vaccines for paediatric and adult use
- Viral vector delivery platforms
- RSV and influenza immunisation strategies
- Next-generation adjuvants and formulations
- Vaccine uptake and health literacy campaigns
- Immunisation equity and access in global settings
- Real-world data communication post-launch
- Immunology education for HCPs
Our approach sets us apart
Elion works closely with client teams to deliver high-quality medical writing with strategic insight and adaptability.
We take the time to understand your communication goals, timelines and audience, and we tailor our support accordingly. We communicate scientific content with accuracy and purpose. Whether collaborating on a single deliverable or on a multi-phase programme, we bring consistency and attentiveness to every project.
01
Define
Aligning on goals: we begin with a kick-off call and written brief to clarify objectives, timelines, audience, and deliverables. This ensures a shared understanding and smooth project setup.
02
Create
Developing content: we draft clear and engaging content in collaboration with your team. Messaging is grounded in evidence and tailored for your audience.
03
Refine
Reviewing and improving: we edit, fact check and integrate feedback to ensure accuracy, consistency and alignment with industry standards.
04
Enhance
Optimising outputs: we refine visuals, formatting and structure to maximise impact and engagement across all intended channels.
05
Deliver
Finalising and measuring impact: we prepare final deliverables, ready for submission, presentation or distribution. We can also help define success metrics and gather performance insights to inform future projects.
Expertise in virology writing
At Elion, we work closely with healthcare organisations and pharmaceutical companies.
We understand how demanding it can be to keep pace with new developments and tight timelines in vaccines and virology. Our writers bring expertise in mRNA and viral vector vaccines, immunology, immunisation strategies and more to your communications.
Virology FAQs
Elion provides expert medical communications support across the virology landscape, including emerging viral infections, antiviral therapies, vaccines and immunisations. Our team has experience in respiratory viruses, hepatitis, HIV and vaccine-preventable diseases.
In-depth experience with vaccine science: from mRNA platforms to adjuvants and viral vector design, we understand the unique challenges of vaccine development and communication.
Scientific rigour and accelerated delivery: We meet tight timelines without sacrificing accuracy, helping clients publish quickly while staying in line with evolving guidelines.
Strategic flexibility: Whether you need manuscript preparation, HCP education or public-facing content, our team scales to your needs.
We create accurate, compelling content for vaccine education, HCP training and public health campaigns. Whether it’s COVID-19, influenza or paediatric immunisations, we help clients communicate the science and benefits of vaccination effectively.
Elion develops content for publications, slide decks, mechanism of action and immunisation explainers, key opinion leader materials and plain language summaries. We support the full spectrum of virology communications, from clinical trial messaging to post-launch education.
Yes. We have extensive experience supporting virology clinical trials, including those for vaccines and immunotherapies, with services spanning protocol support, clinical study report writing and evidence-based messaging.
Absolutely. Elion can create scalable, localisation-ready materials to support both global vaccine launches and national immunisation efforts, helping clients engage HCPs, patients and policymakers.
We translate complex virology and immunisation science into clear, accessible content to empower patients with information about viral diseases, vaccine safety and preventive care.
